Avelumab in gastric cancer

Giandomenico Roviello, Alberto D'Angelo, Daniele Generali, Matteo Pittacolo, Monica Ganzinelli, Giandomenica Iezzi, Nicolò De Manzini, Navid Sobhani

Research output: Contribution to journalArticle

Abstract

Gastric cancer (GC) is the fifth most common malignancy and the third cause of cancer-related deaths worldwide. Currently, surgery and chemotherapy remain the main therapeutic options and the prognosis of the disease is still poor in the metastatic setting. Avelumab is a human IgG1 antibody directed against PD-L1 approved for Merkel cell carcinoma and urothelial carcinoma that could be useful also for the treatment of GC. This review describes the chemical structure, the pharmacologic properties and the current knowledge of the efficacy of avelumab in the treatment of GC from the data available on the first and later phase clinical trials. The ongoing studies testing this drug either alone or in combination with other drugs are also described.

Original languageEnglish
Pages (from-to)759-768
Number of pages10
JournalImmunotherapy
Volume11
Issue number9
DOIs
Publication statusPublished - May 16 2019

Fingerprint

Stomach Neoplasms
Merkel Cell Carcinoma
Pharmaceutical Preparations
Neoplasms
Therapeutics
Immunoglobulin G
Clinical Trials
Carcinoma
Drug Therapy
Antibodies
avelumab

Keywords

  • avelumab
  • gastric cancer
  • immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Roviello, G., D'Angelo, A., Generali, D., Pittacolo, M., Ganzinelli, M., Iezzi, G., ... Sobhani, N. (2019). Avelumab in gastric cancer. Immunotherapy, 11(9), 759-768. https://doi.org/10.2217/imt-2019-0011

Avelumab in gastric cancer. / Roviello, Giandomenico; D'Angelo, Alberto; Generali, Daniele; Pittacolo, Matteo; Ganzinelli, Monica; Iezzi, Giandomenica; De Manzini, Nicolò; Sobhani, Navid.

In: Immunotherapy, Vol. 11, No. 9, 16.05.2019, p. 759-768.

Research output: Contribution to journalArticle

Roviello, G, D'Angelo, A, Generali, D, Pittacolo, M, Ganzinelli, M, Iezzi, G, De Manzini, N & Sobhani, N 2019, 'Avelumab in gastric cancer', Immunotherapy, vol. 11, no. 9, pp. 759-768. https://doi.org/10.2217/imt-2019-0011
Roviello G, D'Angelo A, Generali D, Pittacolo M, Ganzinelli M, Iezzi G et al. Avelumab in gastric cancer. Immunotherapy. 2019 May 16;11(9):759-768. https://doi.org/10.2217/imt-2019-0011
Roviello, Giandomenico ; D'Angelo, Alberto ; Generali, Daniele ; Pittacolo, Matteo ; Ganzinelli, Monica ; Iezzi, Giandomenica ; De Manzini, Nicolò ; Sobhani, Navid. / Avelumab in gastric cancer. In: Immunotherapy. 2019 ; Vol. 11, No. 9. pp. 759-768.
@article{6b1dc7cec08c485c85a8128fb040a32d,
title = "Avelumab in gastric cancer",
abstract = "Gastric cancer (GC) is the fifth most common malignancy and the third cause of cancer-related deaths worldwide. Currently, surgery and chemotherapy remain the main therapeutic options and the prognosis of the disease is still poor in the metastatic setting. Avelumab is a human IgG1 antibody directed against PD-L1 approved for Merkel cell carcinoma and urothelial carcinoma that could be useful also for the treatment of GC. This review describes the chemical structure, the pharmacologic properties and the current knowledge of the efficacy of avelumab in the treatment of GC from the data available on the first and later phase clinical trials. The ongoing studies testing this drug either alone or in combination with other drugs are also described.",
keywords = "avelumab, gastric cancer, immunotherapy",
author = "Giandomenico Roviello and Alberto D'Angelo and Daniele Generali and Matteo Pittacolo and Monica Ganzinelli and Giandomenica Iezzi and {De Manzini}, Nicol{\`o} and Navid Sobhani",
year = "2019",
month = "5",
day = "16",
doi = "10.2217/imt-2019-0011",
language = "English",
volume = "11",
pages = "759--768",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "9",

}

TY - JOUR

T1 - Avelumab in gastric cancer

AU - Roviello, Giandomenico

AU - D'Angelo, Alberto

AU - Generali, Daniele

AU - Pittacolo, Matteo

AU - Ganzinelli, Monica

AU - Iezzi, Giandomenica

AU - De Manzini, Nicolò

AU - Sobhani, Navid

PY - 2019/5/16

Y1 - 2019/5/16

N2 - Gastric cancer (GC) is the fifth most common malignancy and the third cause of cancer-related deaths worldwide. Currently, surgery and chemotherapy remain the main therapeutic options and the prognosis of the disease is still poor in the metastatic setting. Avelumab is a human IgG1 antibody directed against PD-L1 approved for Merkel cell carcinoma and urothelial carcinoma that could be useful also for the treatment of GC. This review describes the chemical structure, the pharmacologic properties and the current knowledge of the efficacy of avelumab in the treatment of GC from the data available on the first and later phase clinical trials. The ongoing studies testing this drug either alone or in combination with other drugs are also described.

AB - Gastric cancer (GC) is the fifth most common malignancy and the third cause of cancer-related deaths worldwide. Currently, surgery and chemotherapy remain the main therapeutic options and the prognosis of the disease is still poor in the metastatic setting. Avelumab is a human IgG1 antibody directed against PD-L1 approved for Merkel cell carcinoma and urothelial carcinoma that could be useful also for the treatment of GC. This review describes the chemical structure, the pharmacologic properties and the current knowledge of the efficacy of avelumab in the treatment of GC from the data available on the first and later phase clinical trials. The ongoing studies testing this drug either alone or in combination with other drugs are also described.

KW - avelumab

KW - gastric cancer

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85066042477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066042477&partnerID=8YFLogxK

U2 - 10.2217/imt-2019-0011

DO - 10.2217/imt-2019-0011

M3 - Article

C2 - 31060469

AN - SCOPUS:85066042477

VL - 11

SP - 759

EP - 768

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 9

ER -